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Imaging Atherosclerotic Plaque Inflammation by
Fluorodeoxyglucose With Positron Emission Tomography
Ready for Prime Time?
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Renu Virmani, MD,§ Josef Machac, MD, Mike Klimas, PHD,# Nobuhiro Tahara, MD, PHD,**
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Cambridge, England; Irvine, California; New York, New York; Gaithersburg, Maryland;
West Point, Pennsylvania; Kurume City, Japan; and Boston, Massachusetts
Inflammation is a determinant of atherosclerotic plaque rupture, the event leading to most myocardial infarc-
tions and strokes. Although conventional imaging techniques identify the site and severity of luminal stenosis,
the inflammatory status of the plaque is not addressed. Positron emission tomography imaging of atherosclero-
sis using the metabolic marker fluorodeoxyglucose allows quantification of arterial inflammation across multiple
vessels. This review sets out the background and current and potential future applications of this emerging bi-
omarker of cardiovascular risk, along with its limitations. (J Am Coll Cardiol 2010;55:2527–35) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.061i
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ntherosclerosis remains the leading killer in the U.S. Inflam-
ation (1) and plaque erosion (2) are the main drivers of
linical events such as myocardial infarction, which usually
esult from the sudden rupture of macrophage-rich atheroscle-
otic plaques. Although anatomic imaging with X-ray angiog-
aphy can identify arterial stenoses, no information is obtained
bout the degree of plaque inflammation.
Fluorodeoxyglucose (FDG) with positron emission to-
ography (PET) is a molecular imaging technique that is
ighly sensitive to metabolically active processes using
lucose as a fuel. FDG is an analog of glucose that is
dministered intravenously, with a half-life of 110 min. It is
enerally allowed to circulate for an hour before PET
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009, accepted December 14, 2009.maging begins. PET imaging has a relatively low spatial
esolution (3 to 4 mm), mandating the use of concurrent
tructural imaging (either computed tomography [CT] or
agnetic resonance imaging [MRI]) to guide localization of
he FDG signal.
In oncology, FDG uptake by tumor makes PET the gold
tandard for detection of metastatic disease (3). In cardiol-
gy, FDG PET is routinely used to estimate myocardial
lucose consumption; in jeopardized myocardium, uptake of
DG implies viability and likely positive response to myo-
ardial revascularization (4).
Recently, arterial FDG PET imaging has been suggested
s a biomarker to report on the metabolic activity of
therosclerosis (5). As well as identifying symptomatic
esions (6), it may have a role in monitoring the response of
therosclerosis to therapy (7). Future applications might
nclude the prediction of plaque rupture and clinical events.
This review covers background, current applications, and
ighlights challenges for FDG PET atherosclerosis
maging.
ationale for FDG PET Atherosclerosis Imaging:
laque Inflammation
laque rupture, the most common cause of myocardial
nfarction, accounts for approximately 70% of all sudden
eaths. The thin cap fibroatheroma (Fig. 1) is now recog-
ized as the plaque type that is most likely to rupture. It isdentified histologically by a large necrotic core, a thin
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FDG PET Atheroma Imaging June 8, 2010:2527–35overlying fibrous cap, and mac-
rophage and T-lymphocyte infil-
tration (8). There may also be
revascularization and spotty cal-
cification within the plaque. The
degree of macrophage infiltration
correlates well with lesion pro-
gression (9). Thin cap fibroathe-
romas have a volume of approx-
imately 0.1 mm3 and are more
common in the proximal coro-
nary arteries. Fibrous cap thin-
ning is thought to arise from
depletion of collagens caused by
an imbalance between synthesis
nd breakdown of extracellular matrix attributed to a host of
egrading metalloproteinases produced by macrophages
10,11).
ptake of FDG Into Plaque Cells
ecause FDG is a glucose analog, cells participating in the
nflammatory process must use exogenous glucose as a fuel
f they are to be detected by PET imaging. It is also
dvantageous that inflammatory cells have a substantially
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CT  computed
tomography
FDG  fluorodeoxyglucose
GLUT  glucose
transporter protein
MRI  magnetic resonance
imaging
PET  positron emission
tomography
Figure 1 Pathology of High-Risk Plaque
Thin-cap fibroatheroma, the precursor lesion to plaque rupture. (A) An eccentric pl
(Movat pentachrome stain). (B) Higher magnification image of the thin fibrous cap
debris. (C) Higher magnification represented by the area within the black box in A
scattered CD45RO T lymphocytes.igher rate of glucose uptake than neighboring cell types
12–14), which they use to power cellular motility and
hagocytosis (15,16). Macrophages can also metabolize free
atty acids; this needs oxygen to generate adenosine triphos-
hate, whereas glucose metabolism does not. The interior of
plaque is an anaerobic area even in the presence of an
ncreased vaso vasorum (17). Thus, glucose is the major
ubstrate for macrophages resident in plaque (18).
Like glucose itself, facilitative transport via the glucose
ransporter protein (GLUT) system is the most important
ay for FDG to enter human cells (19). After entry, FDG
ecomes phosphorylated to FDG-6-phosphate by hexoki-
ase. Activated macrophages have 10 times higher levels of
exokinase activity than resting cells (20). In contrast to
lucose-6-phosphate, FDG-6-phosphate cannot be metab-
lized further along the glycolytic pathway and therefore
ccumulates within cells in direct proportion to their met-
bolic activity. This phenomenon is referred to as metabolic
rapping. FDG can theoretically escape from the cell by
ephosphorylation. However, this is generally a negligible
rocess because of the low intracellular levels of the dephos-
horylation enzyme. The FDG uptake of any cell is thus
etermined by several factors: the expression of GLUTs
hrough the cell membrane, the activity of the hexokinase
ith a large superficial necrotic core (NC) and overlying thin-fibrous cap (FC)
y infiltrated by inflammatory cells. The necrotic core is formed by loose cellular
ing a thin fibrous cap infiltrated by CD68 macrophages. (D) Similar area withaque w
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June 8, 2010:2527–35 FDG PET Atheroma Imagingnzyme, and the rate of FDG dephosphorylation (21,22)
Fig. 2). Additionally, uptake of FDG in macrophages in
ulture depends on the prevailing glucose concentration, the
ulture duration, and the degree of macrophage activation
23,24) (Fig. 3). In normal monocytes, GLUT 3 expression
s present at higher concentrations than GLUT 1; the
nsulin-sensitive GLUT 4 subtype is not detectable. Cellular
ctivation increases both GLUT 1 and 3 expression. In
ddition, macrophages show a massive overproduction of
exokinase during stimulation (24,25). However, it is also
nown that other plaque cell types, including endothelial cells,
re capable of accumulating FDG, at least in culture (26).
Because diabetic patients are at high risk of the compli-
ations of atherosclerosis, it is important that the effect of
yperglycemia on plaque FDG uptake be considered. In
umors, FDG accumulation is diminished during hypergly-
emia (27), owing to direct competition between FDG and
lucose for cellular entry. However, cell culture experiments
FDG
Glucose
FDG
Glucose
GLUT
Plasma
G
G
Figure 2 FDG Uptake
Metabolic trapping of fluorodeoxyglucose (FDG). GLUT  glucose transporter.
Figure 3 Effects of Culture Duration, Glucose Concentration,
and Cellular Activators on FDG Uptake
Fluorodeoxyglucose (FDG) uptake is increased with culture duration (left) and
is inhibited with increasing (unlabeled) glucose concentrations in culture
medium (center). Activation by lipopolysaccharide (LPS) for 24 h further
enhanced FDG uptake (right). Modified from Deichen et al. (23).suggest that moderate hyperglycemia, up to 250 mg/dl, does
ot adversely affect FDG uptake in inflammatory cells (28,29).
eproducibility of atheroma imaging with FDG is still likely to
e worse in those with high blood sugar at the time of imaging
ompared with nomoglycemic subjects (30).
To perform vascular PET studies, a longer FDG circu-
ation time than that for oncology PET imaging is ad-
ised—at least 90 min (5,31). This is to allow sufficient
DG accumulation in the arterial wall and to permit blood
evels of FDG to become reduced by decay and excretion.
arly dynamic PET studies determined that the optimum time
rom FDG injection to imaging was approximately 3 h (5).
ubsequent work showed that 2 h could be used without
ignificant degradation of the arterial FDG signal (6). It must
e noted that if earlier time points are chosen, then the partial
olume effect of FDG activity spilling into the wall from the
rtery lumen will be more apparent. Although shorter FDG
irculation times have been used (32), the potential for partial
olume errors may be greater with this strategy (33).
eview of FDG PET Atherosclerosis Imaging:
re-Clinical Studies
nimal models of atherosclerosis have been used to explore
he basis of arterial FDG uptake. The first article to suggest
link between experimental atherosclerosis and FDG up-
ake was published in 1996 (34). In a larger study in the
abbit model of atherosclerosis, FDG uptake correlated
ignificantly with plaque macrophage content (r  0.81,
 0001) (35), a result that has been replicated by several
thers (36–40). Tawakol et al. (38) showed that although
DG uptake correlated strongly with macrophage infiltra-
ion (r  0.93, p  0.002), the most inflamed areas of
laque accumulated almost 20 times more FDG than
ontrol arteries. In addition, there was no relationship
etween FDG uptake and plaque size, whole vessel size, or
he density of plaque smooth muscle cells. These studies
upport the hypothesis that the metabolic signal measured
n plaques is due predominantly to the presence of macro-
hages. Aziz et al. (41) took this concept further. They
FDG-6-phosphate
Tissue
G-6-phosphate
Glycolysis
Metabolic trapping
inase
inase
sphatase
sphataseHexok
Hexok
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-6-phohowed, again in a rabbit model of atherosclerosis, that
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FDG PET Atheroma Imaging June 8, 2010:2527–35hen plaque rupture was promoted by venom injection,
nly those aortic plaques with the highest pre-rupture FDG
evels progressed to rupture and thrombosis. This suggests a
ossible role for FDG imaging to predict future plaque
upture events.
In a mouse model of atherosclerosis, autoradiography has
emonstrated increased uptake of FDG after cholesterol feed-
ng in both wild-type (42) and ApoE (43,44) mice. Other
tudies have not been able to replicate these findings (45),
ossibly because an early imaging time point was chosen (46).
A potentially useful application of FDG imaging of
therosclerosis might be to track reductions in inflammation
hat occur with therapy. This has been demonstrated using a
abbit model of atheroma, in which a significant lowering of
ortic FDG uptake was demonstrated after 3 months treat-
ent with the anti-inflammatory drug probucol (47). More
ecently, withdrawal from a high cholesterol diet after a period
f high fat feeding was associated with a marked reduction in
DG uptake in the aorta of atherosclerotic rabbits (39).
DG PET Atherosclerosis Imaging: Clinical Studies
DG uptake in the arterial wall was first noted incidentally
n the aorta of patients undergoing PET imaging for cancer
taging (48).
In the first prospective study using FDG PET to quantify
nflammation in atherosclerosis, Rudd et al. (5) measured
ncreased carotid artery FDG uptake in symptomatic lesions
f patients with recent transient ischemic attack (27%
reater than asymptomatic carotid plaque). In related ex
ivo experiments, there was accumulation of tritiated deoxy-
lucose within macrophage-rich areas of the excised carotid
laques (5). The same group reported increased FDG uptake
n the culprit vertebral artery of patients with symptomatic
osterior territory stroke (6). Arterial inflammation imaging
ith FDG PET has now been extended from the carotid and
ertebral arteries to the aorta (49,50) and iliac and femoral
rteries (51,52). Anatomically, FDG uptake may be wide-
pread, particularly affecting the carotid arteries (53) and
roximal aorta (54). It has also been demonstrated that arteries
natomically close have FDG uptake levels more highly cor-
elated than those more distant from each other (54). This
ints at a form of local regulation of inflammation. These
tudies were recently summarized by Menezes et al. (32).
The relationship between arterial FDG signal and plaque
nflammation has been examined in humans and shows
trong concordance (r  0.96, p  0.001) (31), as in animal
tudies. Others have replicated these findings (55). As well
s being linked to macrophage content, FDG signal corre-
ates with levels of several circulating inflammatory biomar-
ers (54,56,57). Recently, Græbe et al. (58,59) demon-
trated a positive correlation between FDG uptake and the
xpression levels of several genes, including CD68, that are
ssociated with atherosclerotic plaque inflammation. As
uggested by early studies in oncology patients, advancing
ge (60,61), male sex (54), and the presence of other aardiovascular risk factors (57,62,63) are associated with an
ncreased arterial FDG uptake. Several groups have also
oted FDG uptake in inflammatory arterial conditions
elated to atherosclerosis including giant cell arteritis and
olymyalgia rheumatica (64).
Plaques defined as high-risk by MRI (large lipid core
65], intra-plaque hemorrhage [66], or on ultrasound [67])
ave greater FDG uptake than those with more stable
henotypes. Using PET/CT imaging, FDG uptake is well
orrelated with hyperenhancement of plaque after adminis-
ration of a macrophage-specific iodinated contrast agent
68) and is negatively correlated with the degree of arterial
alcification (69). Finally, arterial FDG uptake is greater in
rteries with high pulse wave velocities (60), another surro-
ate marker of vascular dysfunction.
oronary Artery FDG PET Imaging
everal technical obstacles must be overcome before FDG
ET imaging can be applied to measure inflammation in
oronary artery plaque. First, under normal conditions, the
yocardium avidly accumulates FDG (reflecting its prefer-
nce for glucose metabolism). Second, cardiac motion is
onsiderable, especially in the distal coronary arteries, lead-
ng to blurring of any coronary plaque FDG uptake. To
omplicate matters further, CT data, needed for localization
f any arterial FDG activity, are acquired over approxi-
ately 5 s, during breath-hold and using electrocardio-
raphic gating. Routine PET acquisitions are typically
ngated and obtained over 15 min. As a result, there may
e large spatial shifts between the PET and CT datasets.
inally, the small size of coronary plaque requires a
elatively high degree of focal FDG accumulation before
detectable signal can be measured due to the modest
esolution of PET.
Despite these challenges, several groups have reported
DG accumulation in association with coronary vessels
69–73). Dunphy et al. (69) provided an early account of
DG activity in the coronary arteries. In that study, fortu-
tously low myocardial FDG uptake allowed identification
f FDG uptake in the proximal coronary arteries. Since that
eport, the use of a pre-imaging diet to suppress myocardial
DG uptake has been described. This consists of several
igh-fat, low-carbohydrate meals leading up to FDG injec-
ion (74). High-fat diets are superior to fasting alone,
resumably by causing the myocardium to shift toward
etabolizing free fatty acids rather than glucose. Wykr-
ykowska et al. (72) reported on 32 patients treated for
alignancy who underwent FDG PET after this diet with
oncomitant cardiac catheterization. They identified FDG
ptake in 15 of 32 patients in 1 coronary segments. A
rend toward significance between the presence of angio-
raphic disease and FDG signal in the vessel was reported
p  0.07; 80 vessels examined). Similarly, Williams et al.
71) noted colocalization of coronary artery FDG uptake
nd FDG uptake at several extracardiac sites (87% concor-
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June 8, 2010:2527–35 FDG PET Atheroma Imagingance) in their retrospective analysis of patients undergoing
ancer imaging. They also found that the high-fat diet to
educe myocardial FDG uptake did lower FDG accumula-
ion by noncardiac inflammatory lesions. This is likely
ecause the diet acts mainly on insulin-dependent myocar-
ial GLUT 4 subtypes (absent in plaque macrophages)
ather than GLUT 1 and 3 present on inflammatory cells
ithin the plaque.
Recently, Rogers et al. (75) compared FDG uptake in
ulprit coronary artery lesions in patients with acute coro-
ary syndrome (ACS) and stable angina controls (Fig. 4).
hey reported significantly higher coronary artery FDG up-
ake in plaques in ACS patients. Additionally, they noted
igher FDG signals within the left main stem artery and
scending aorta in patients with ACS, a finding consistent
ith the concept that ACS is associated with increased arterial
nflammation.
eproducibility of FDG PET
therosclerosis Imaging
f PET imaging is to be useful in evaluating the effectiveness
f treatments for atherosclerosis, the reproducibility of the
rterial FDG signal must be established. The short-term
nterscan reproducibility for atherosclerosis imaging is ex-
ellent in the carotid, aortic, and peripheral arteries
50,52,55,76), with good interobserver agreement. In addi-
ion, excellent 3-month reproducibility in the carotid artery
as been demonstrated in bystander plaque in patients
CT
Angiogram
Fused
PET and CT
Images
LV
LV
RCA
RCA
A
C
Figure 4 Coronary Artery FDG Uptake
(A) Axial cardiac computed tomography (CT) demonstrating a plaque in the right co
(C) Fused positron emission tomography (PET)/CT image demonstrating fluorodeo
artery plaque. F  front; LV  left ventricle.maged before and after carotid endarterectomy (55). Re-
roducibility statistics for FDG PET compare favorably
ith those published for MRI and ultrasound measures of
laque burden (77,78). In the longer term, there seems to be
degree of progression of FDG uptake in arterial segments,
ith smaller changes noted in calcified segments in the same
atients (79,80). This situation may be due to active,
DG-avid plaques becoming burned out, with calcification
manifestation of this late phase of atherosclerosis (81,82).
elationship of FDG Uptake to Vascular Events
ending the results of large, ongoing outcome trials, there is
ome evidence that arterial FDG uptake is related to
ubsequent risk of both plaque rupture and clinical events.
n a study of patients with cancer, investigators identified
hose with (n  45) and without (n  56) arterial FDG
ptake. Patients with the highest FDG uptake were more
ikely to have previously had a vascular event or experienced
ne during the 6 months after PET imaging (83). Similar
esults have been provided by Rominger et al. (84). In
nother study, Arauz et al. (85) presented some prognostic
ata in patients with symptomatic carotid artery disease;
5% of subjects had high levels of FDG uptake (standard-
zed uptake value2.7). Those in the high FDG group had
oorer outcomes over the next 6 months (recurrent stroke,
eath, or restenosis of stented arteries) than subjects with
nitially lower FDG levels. The High Risk Plaque Initiative
s a prospective, event-driven study of 6,500 volunteers at
Plaque
Stent
Plaque
Stent
B
D
artery (RCA). This is seen close up in B at the origin of an intracoronary stent.
se (FDG) uptake within the RCA lesion. (D) FDG uptake in the lipid-rich coronaryronary
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FDG PET Atheroma Imaging June 8, 2010:2527–35isk of cardiovascular disease. Baseline imaging includes
ascular ultrasound, MRI, CT, and FDG PET/CT. This
tudy will test the power of both imaging and circulating
iomarkers to predict cardiovascular events over a 3-year
ollow-up period. It is hoped that studies of this kind will
dentify whether atherosclerosis imaging is superior to
isk-scoring algorithms for predicting cardiovascular events.
an Arterial FDG Uptake
e Modified With Therapy?
useful application of this technology is for testing the
ffectiveness of potential antiatherosclerosis drugs. The
ffects of simvastatin therapy on arterial FDG uptake in
atients being screened for cancer has been investigated (7).
DG uptake in carotid plaques was significantly reduced
fter 3 months of simvastatin therapy, but no effect was seen
n patients not given statins (Fig. 5). The extent of reduction
f FDG uptake was positively correlated with an increase in
igh-density lipoprotein cholesterol and apolipoprotein A-1
evels independent of a decrease in low-density lipoprotein
holesterol and apolipoprotein B. The maximum dose of
imvastatin used in the study (20 mg) was low compared
ith current recommendations, and one can speculate that a
ore potent dose coupled with a vascular-specific PET
Baseli
PET/CT
PET
D
ie
t
Si
m
va
st
at
in
PET
Basel
PET/CT
Figure 5 FDG Uptake Is Reduced by Simvastatin
FDG PET images at baseline (left) and after 3 months of intervention (right) with
had no effect on FDG uptake (top, arrows) in carotid arteries and aortic arch. On
arrows). The coregistered PET and CT images allow identification of tracer localiza
tions as in Figure 4.maging protocol might have produced more impressive
esults (86).
Another study (87) examined the effect of risk factor
odification on arterial FDG uptake. After 17 months,
here was a 65% reduction in the number of vascular regions
hat accumulated FDG. Again, the magnitude of the
eduction closely paralleled the increase in high-density
ipoprotein seen in the patient group as a whole. In a further
ntervention study, a trial of B vitamins on arterial inflamma-
ion was negative, a result supported by the lack of any effect on
ther markers of arterial disease of these vitamins (88).
onclusions
lthough FDG PET has proven useful for quantifying
nflammation within atherosclerosis, there is intense interest
n developing tracers that are more specific for features of
igh-risk plaques. This is theoretically most important for
oronary imaging, where imaging of the relatively small size
laques would benefit from higher accumulation of tracer,
n the one hand, and from less myocardial background
ptake on the other. Several other molecules targeting
laque inflammation may be suitable for PET imaging
89,90). Additionally, there are other cellular components
esides inflammation that might identify vulnerable/high-risk
Post-treatment
Post-treatment
modification (top) or simvastatin therapy (bottom). Dietary modification alone
er hand, FDG uptake was markedly reduced by simvastatin treatment (bottom,
the carotid arteries (red arrowheads). Modified from Tahara et al. (7). Abbrevia-ne
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June 8, 2010:2527–35 FDG PET Atheroma Imaginglaques, such as neovascularization (91) and apoptosis (92).
lthough such progress in tracer development is encouraging,
t is worth noting that in oncology, more specific PET imaging
gents have not been able to replace the high target activity of
DG in most cases.
In atherosclerosis imaging, it is likely that FDG PET will
ontinue to find applications in cardiovascular risk predic-
ion and noninvasive antiatherosclerosis drug testing. Lim-
tations, such as the expense of PET and radiation burden,
ill likely limit its use to larger centers. Multicenter trials
sing this technology are already under way, and standard-
zation of imaging acquisition and analysis protocols will
ssume more importance. Finally, the results of prospective
tudies such as the High Risk Plaque Initiative should help
o define the place of noninvasive imaging such as FDG
ET for the identification of patients at high risk of
ardiovascular events.
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